EGFR and non-small cell lung carcinoma: EGFR tyrosine kinase inhibitors (EGFR‐TKIs) are the systemic therapy recommended by most treatment guidelines for patients with EGFR‐mutant NSCLC and BM.1, 2, 3, 4, 5